Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCT BriaCell Therapeutics	C$10.60 -3.8%	C$10.60	C$3.50 ▼ C$15.75	C$168.68M	N/A	12,671 shs	3,402 shs
FRX Forest Road Acquisition		$10.30	$9.72 ▼ $18.20	$450M	N/A	2.07 million shs	40,482 shs
IPA ImmunoPrecise Antibodies	$2.02 +6.3%	$1.38	$0.27 ▼ $2.41	$93.22M	0.49	4.19 million shs	679,986 shs
MBX MBX Biosciences	$12.53 +11.3%	$12.13	$4.81 ▼ $27.50	$418.80M	N/A	325,960 shs	293,739 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCT BriaCell Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
FRX Forest Road Acquisition	0.00%	0.00%	0.00%	0.00%	0.00%
IPA ImmunoPrecise Antibodies	-5.00%	+3.83%	+28.38%	+282.29%	+160.31%
MBX MBX Biosciences	-7.40%	-10.21%	-13.65%	+9.64%	+1,125,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCT BriaCell Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FRX Forest Road Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IPA ImmunoPrecise Antibodies	2.4548 of 5 stars	3.5	3.0	0.0	0.0	3.2	0.0	0.6
MBX MBX Biosciences	2.5731 of 5 stars	3.5	0.0	0.0	0.0	3.1	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCT BriaCell Therapeutics	0.00	N/A	C$15.00	41.51% Upside
FRX Forest Road Acquisition	0.00	N/A	N/A	N/A
IPA ImmunoPrecise Antibodies	3.00	Buy	$4.00	98.02% Upside
MBX MBX Biosciences	3.00	Buy	$37.63	200.28% Upside

Current Analyst Ratings Breakdown

Latest MBX, BCT, IPA, and FRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/5/2025	MBX MBX Biosciences	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$38.00
7/16/2025	MBX MBX Biosciences	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$38.00

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCT BriaCell Therapeutics	N/A	N/A	C$3.34 per share	3.17	C$3.60 per share	N/A
FRX Forest Road Acquisition	N/A	N/A	N/A	N/A	$0.56 per share	N/A
IPA ImmunoPrecise Antibodies	$17.59M	5.30	N/A	N/A	$0.37 per share	5.46
MBX MBX Biosciences	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCT BriaCell Therapeutics	N/A	-C$0.38	N/A	∞	N/A	N/A	N/A	N/A	N/A
FRX Forest Road Acquisition	-$7.92M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
IPA ImmunoPrecise Antibodies	-$21.69M	-$0.68	N/A	N/A	N/A	-122.10%	-40.62%	-22.19%	9/15/2025 (Estimated)
MBX MBX Biosciences	N/A	-$4.54	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest MBX, BCT, IPA, and FRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
7/29/2025	Q4 2025	IPA ImmunoPrecise Antibodies	-$0.02	-$0.04	-$0.02	-$0.04	$7.89 million	$5.06 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCT BriaCell Therapeutics	N/A	N/A	N/A	N/A	N/A
FRX Forest Road Acquisition	N/A	N/A	N/A	N/A	N/A
IPA ImmunoPrecise Antibodies	N/A	N/A	N/A	N/A	N/A
MBX MBX Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCT BriaCell Therapeutics	0.05	129.63	128.68
FRX Forest Road Acquisition	N/A	0.37	0.37
IPA ImmunoPrecise Antibodies	0.49	2.08	1.85
MBX MBX Biosciences	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCT BriaCell Therapeutics	N/A
FRX Forest Road Acquisition	N/A
IPA ImmunoPrecise Antibodies	6.70%
MBX MBX Biosciences	N/A

Insider Ownership

Company	Insider Ownership
BCT BriaCell Therapeutics	N/A
FRX Forest Road Acquisition	N/A
IPA ImmunoPrecise Antibodies	6.83%
MBX MBX Biosciences	52.19%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCT BriaCell Therapeutics	5	15.91 million	N/A	Not Optionable
FRX Forest Road Acquisition	N/A	37.50 million	N/A	Not Optionable
IPA ImmunoPrecise Antibodies	80	46.15 million	43.00 million	Not Optionable
MBX MBX Biosciences	36	33.42 million	N/A	N/A

MBX, BCT, IPA, and FRX Headlines

Recent News About These Companies

MBX Biosciences Reports Progress and Financial Stability

August 11 at 12:50 AM | tipranks.com

MBX Biosciences (NYSE:MBX) Earns Outperform Rating from Analysts at Mizuho

August 8, 2025 | americanbankingnews.com

MBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

August 7, 2025 | globenewswire.com

MBX Biosciences (NYSE:MBX) Coverage Initiated at Mizuho

August 6, 2025 | marketbeat.com

Mizuho Initiates Coverage of MBX Biosciences (MBX) with Outperform Recommendation

August 5, 2025 | msn.com

TD Asset Management Inc Raises Stock Holdings in MBX Biosciences, Inc. (NYSE:MBX)

August 5, 2025 | marketbeat.com

MBX Biosciences Inc. (MBX) Stock Price Today - WSJ

August 2, 2025 | wsj.com

MBX Biosciences (NYSE:MBX) Shares Up 15.7% - What's Next?

July 26, 2025 | marketbeat.com

MBX Biosciences, Inc. (NYSE:MBX) Receives Average Rating of "Buy" from Analysts

July 19, 2025 | marketbeat.com

Oppenheimer Initiates Coverage of MBX Biosciences (MBX) with Outperform Recommendation

July 17, 2025 | msn.com

Oppenheimer Initiates Coverage on MBX Biosciences (NYSE:MBX)

July 16, 2025 | marketbeat.com

MBX Biosciences Inc Executives - Morningstar

June 25, 2025 | morningstar.comM

MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development - Morningstar

June 24, 2025 | morningstar.comM

MBX Biosciences Inc Chart - Morningstar

June 24, 2025 | morningstar.comM

MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development

June 23, 2025 | globenewswire.com

MBX Biosciences Submits IND for Obesity Treatment

June 16, 2025 | tipranks.com

MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity

June 16, 2025 | globenewswire.com

MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions

June 10, 2025 | globenewswire.com

mbx biosciences announces board changes and director elections

June 7, 2025 | uk.investing.com

MBX Biosciences: Consider Peptide Developer With GLP Drugs As A Speculative Buy

May 31, 2025 | seekingalpha.com

MBX Biosciences to Participate in June Investor Conferences

May 20, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

MBX, BCT, IPA, and FRX Company Descriptions

BriaCell Therapeutics CVE:BCT

C$10.60 -0.42 (-3.81%)

As of 12/30/2021

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.

Forest Road Acquisition NYSE:FRX

Forest Road Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the technology, media, and telecommunications space. The company was founded in 2020 and is based in New York, New York.

ImmunoPrecise Antibodies NASDAQ:IPA

$2.02 +0.12 (+6.32%)

Closing price 04:00 PM Eastern

Extended Trading

$2.00 -0.02 (-0.74%)

As of 07:55 PM Eastern

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.

MBX Biosciences NYSE:MBX

$12.53 +1.27 (+11.28%)

Closing price 04:00 PM Eastern

Extended Trading

$12.47 -0.06 (-0.48%)

As of 05:41 PM Eastern

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time